» Articles » PMID: 30410055

Heterogeneous Fenton Reaction Enabled Selective Colon Cancerous Cell Treatment

Overview
Journal Sci Rep
Specialty Science
Date 2018 Nov 10
PMID 30410055
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A selective colon cancer cell therapy was effectively achieved with catalase-mediated intra-cellular heterogeneous Fenton reactions triggered by cellular uptake of SnFeO nanocrystals. The treatment was proven effective for eradicating colon cancer cells, whereas was benign to normal colon cells, thus effectively realizing the selective colon cancer cell therapeutics. Cancer cells possess much higher innate hydrogen peroxide (HO) but much lower catalase levels than normal cells. Catalase, an effective HO scavenger, prevented attacks on cells by reactive oxygen species induced from HO. The above intrinsic difference between cancer and normal cells was utilized to achieve selective colon cancer cell eradication through endocytosing efficient heterogeneous Fenton catalysts to trigger the formation of highly reactive oxygen species from HO. In this paper, SnFeO nanocrystals, a newly noted outstanding paramagnetic heterogeneous Fenton catalyst, have been verified an effective selective colon cancerous cell treatment reagent of satisfactory blood compatibility.

Citing Articles

Spermatozoon-propelled microcellular submarines combining innate magnetic hyperthermia with derived nanotherapies for thrombolysis and ischemia mitigation.

Weng P, Liu C, Jheng P, Chiang C, Chen Y, Rethi L J Nanobiotechnology. 2024; 22(1):470.

PMID: 39118029 PMC: 11308583. DOI: 10.1186/s12951-024-02716-w.


Iron metabolism: backfire of cancer cell stemness and therapeutic modalities.

Yu R, Hang Y, Tsai H, Wang D, Zhu H Cancer Cell Int. 2024; 24(1):157.

PMID: 38704599 PMC: 11070091. DOI: 10.1186/s12935-024-03329-x.


Self-Therapeutic Nanomaterials: Applications in Biology and Medicine.

Seaberg J, Clegg J, Bhattacharya R, Mukherjee P Mater Today (Kidlington). 2023; 62:190-224.

PMID: 36938366 PMC: 10022599. DOI: 10.1016/j.mattod.2022.11.007.


Nanomedicine targets iron metabolism for cancer therapy.

Lin L, Chen H, Zhao R, Zhu M, Nie G Cancer Sci. 2021; 113(3):828-837.

PMID: 34962017 PMC: 8898713. DOI: 10.1111/cas.15250.

References
1.
Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

2.
Ahsan H, Ali A, Ali R . Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol. 2003; 131(3):398-404. PMC: 1808645. DOI: 10.1046/j.1365-2249.2003.02104.x. View

3.
Fang J, Seki T, Maeda H . Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009; 61(4):290-302. DOI: 10.1016/j.addr.2009.02.005. View

4.
Peng E, Wang F, Xue J . Nanostructured magnetic nanocomposites as MRI contrast agents. J Mater Chem B. 2020; 3(11):2241-2276. DOI: 10.1039/c4tb02023e. View

5.
Liu Q, Shuhendler A, Cheng J, Rauth A, OBrien P, Wu X . Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells. Breast Cancer Res Treat. 2009; 121(2):323-33. DOI: 10.1007/s10549-009-0473-3. View